Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting

Lijun Tan, Jiangtao Liu, Xiuli Liu, Jie Chen, Zhijun Yan, Huifen Yang, Daxin Zhang, Lijun Tan, Jiangtao Liu, Xiuli Liu, Jie Chen, Zhijun Yan, Huifen Yang, Daxin Zhang

Abstract

Background: This study was designed to mainly evaluate the activity and safety of olanzapine compared with 5-hydroxytryptamine 3(5-HT3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly or moderately emetogenic chemotherapy (HEC or MEC). The second goal was to evaluate the impact of olanzapine on quality of life (QoL) of cancer patients during the period of chemotherapy.

Methods: 229 patients receiving highly or moderately emetogenic chemotherapy were randomly assigned to the test group [olanzapine(O) 10 mg p.o. plus azasetron (A) 10 mg i.v. and dexamethasone (D) 10 mg i.v. on day 1; O 10 mg once a day on days 2-5] or the control group (A 10 mg i.v. and D 10 mg i.v. on day 1; D 10 mg i.v. once a day on days 2-5). All the patients filled the observation table of CINV once a day on days 1-5, patients were instructed to fill the EORTC QLQ-C30 QoL observation table on day 0 and day 6. The primary endpoint was the complete response (CR) (without nausea and vomiting, no rescue therapy) for the acute period (24 h postchemotherapy), delayed period (days 2-5 postchemotherapy), the whole period (days 1-5 postchemotherapy). The second endpoint was QoL during chemotherapy administration, drug safety and toxicity.

Results: 229 patients were evaluable for efficacy. Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05). 214 of 299 patients were evaluable for QoL. Comparing test group with control group in QoL evolution, significant differences were seen in global health status, emotional functioning, social functioning, fatigue, nausea and vomiting, insomnia and appetite loss evolution in favour of the test group (p < 0.01). Both treatments were well tolerated.

Conclusion: Olanzapine can improve the complete response of delayed nausea and vomiting in patients receiving the highly or moderately emetogenic chemotherapy comparing with the standard therapy of antiemesis, as well as improve the QoL of the cancer patients during chemotherapy administration. Olanzapine is a safe and efficient drug for prevention of CINV.

References

    1. Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, du Bois A, Tonato M. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-An update. Support Care Cancer. 2005;13:80–84. doi: 10.1007/s00520-004-0718-y.
    1. Geling O, Eichler HG. Should 5-hyroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23:1289–1294. doi: 10.1200/JCO.2005.04.022.
    1. Musso M, Scalone R, Bonanno V, Crescimanno A, Polizzi V, Porretto F, Bianchini C, Perrone T. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support Care Cancer. 2009;17:205–209. doi: 10.1007/s00520-008-0510-5.
    1. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, Aprepitant protocol 052 study group The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high- dose cisplatin- the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4112–4119. doi: 10.1200/JCO.2003.01.095.
    1. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study Group Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090–3098. doi: 10.1002/cncr.11433.
    1. Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage. 2003;25:578–582. doi: 10.1016/S0885-3924(03)00143-X.
    1. Passik SD, Lundberg J, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E, Cooper M, Dugan W. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage. 2002;23:526–532. doi: 10.1016/S0885-3924(02)00391-3.
    1. Passik SD, Kirsh KL, Theobald DE, Dicherson P, Trowbridge R, Gray D, Beaver M, Comparet J, Brown J. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage. 2003;25:485–488. doi: 10.1016/S0885-3924(03)00078-2.
    1. Passik SD, Navari RM, Jung SH, Nagy C, Vinsor J, Kirsh KL, Loehrer P. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest. 2004;22:383–388. doi: 10.1081/CNV-200029066.
    1. Navari RM, Einhorn LH, Passik SD, Loehrer PJ, Sr, Johnson C, Mayer ML, McClean J, Vinson J, Pletcher W. A phase II trial of olanzapine for the prevention of chemptherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer. 2005;13:529–534. doi: 10.1007/s00520-004-0755-6.
    1. Herrestedt J, koeller JM, Roilla F, Hesketh PJ, Warr D, Rittenberg C, Dicato M. Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer. 2005;13:97–103. doi: 10.1007/s00520-004-0701-7.
    1. Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S, Koeller J, Olver I, Borjeson S, Ballatori E. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer. 2005;13:85–96. doi: 10.1007/s00520-004-0699-x.
    1. American Society of Clinical Oncology. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM. American Society of clinical oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24:2932–2947. doi: 10.1200/JCO.2005.04.8918.
    1. Roila F, Warr D, Clarck-Snow RA, Tonato M, Gralla RJ, Einhorn LH, Herrstedt J. Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer. 2005;13:104–108. doi: 10.1007/s00520-004-0700-8.
    1. Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer. 2006;94:1011–1015. doi: 10.1038/sj.bjc.6603048.
    1. Dube S, Tollefson GD, Thase ME, Briggs SD, Van Campen LE, Case M, Tohen M. Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disord. 2007;9:618–627. doi: 10.1111/j.1399-5618.2007.00491.x.
    1. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. A randomized, double-blind, comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety. 2006;23:364–372. doi: 10.1002/da.20130.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi